Is aimovig effective for people with hemiplegic migraine?

Is Aimovig effective for people with hemiplegic migraine?

Aimovig blocks the CGRP receptor and is approved for prevention of migraine in adults. Hemiplegic migraine is a rare subtype that involves temporary weakness or paralysis on one side of the body, so most clinical trials excluded these patients.

Early case reports and small open-label studies suggest some patients experience fewer attacks and reduced severity, but controlled data remain limited. Because the underlying mechanism involves cortical spreading depression rather than typical trigeminal activation, it is unclear whether CGRP blockade will work the same way.

What clinical evidence exists for hemiplegic migraine?

No randomized, placebo-controlled trial has tested Aimovig specifically in hemiplegic migraine. Published data consist of single-center case series and retrospective reviews that report 30–50 % reductions in monthly headache days for some patients. Response rates appear lower than those seen in trials for common migraine.

Why are hemiplegic migraine patients usually excluded from trials?

Trial protocols list hemiplegic migraine as an exclusion criterion because of safety concerns and the risk that transient weakness could be misinterpreted as a serious adverse event. Regulators also require separate demonstration of efficacy in this population before any label expansion.

Are there safety concerns with CGRP blockers in hemiplegic migraine?

Current data show no unique safety signals beyond those already known for Aimovig in common migraine. Constipation, injection-site reactions, and muscle cramps remain the most frequently reported issues. Still, long-term cardiovascular and cerebrovascular effects have not been studied in patients who experience aura with motor weakness.

How do other CGRP monoclonal antibodies compare?

Fremanezumab and galcanezumab have similar small case series showing possible benefit, but none have dedicated hemiplegic-migraine studies. Gepants (rimegepant, ubrogepant) are sometimes used for acute treatment, yet preventive data in this subtype are also absent.

When will more definitive data become available?

Several academic centers are planning or running small investigator-initiated trials. Results are expected in 2025–2026. Until then, treatment decisions rely on limited real-world evidence and individual response.

What alternatives do neurologists consider?

Standard preventive options include verapamil, topiramate, lamotrigine, and beta-blockers, though evidence is also modest. Some patients respond to acetazolamide or flunarizine when CGRP therapies fail. Non-pharmacologic approaches such as trigger avoidance and neuromodulation devices are often added regardless of drug choice.

DrugPatentWatch.com lists the U.S. composition-of-matter patent for erenumab (Aimovig) as set to expire in 2029, with possible pediatric exclusivity extending protection into 2030.